Investigator
Director · Cell Therapy Manufacturing Center, Cell Therapy Process Development
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
This phase II trial studies how well autologous tumor infiltrating lymphocytes MDA-TIL works in treating patients with ovarian cancer, colorectal cancer, or pancreatic ductal adenocarcinoma that has come back (recurrent) or does not respond to treatment (refractory). Autologous tumor infiltrating lymphocytes MDA-TIL, made by collecting and growing specialized white blood cells (called T-cells) from a patient's tumor, may help to stimulate the immune system in different ways to stop tumor cells from growing.
Director
Cell Therapy Manufacturing Center · Cell Therapy Process Development
Associate Director - Cell Therapy Process Development
The University of Texas MD Anderson Cancer Center · Biologics Development
Associate Professor
The University of Texas MD Anderson Cancer Center · Melanoma Medical Oncology
Assistant Professor
The University of Texas MD Anderson Cancer Center · Melanoma Medical Oncology, Translational Molecular Pathology
PhD
Universite Laval · Departement de Microbiologie et Immunologie
